Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica
- Published on 01/10/2025
- Reading time: 5 min.
Nisa Vorasoot 1,2,3,4, Yahya J. Abdulrahman 2,3, Farrah Mateen 5, James P. Fryer 2,3, Vyanka Redenbaugh 1,2,3, Jessica A. Sagen 3, Abdu K. Musubire 6, Sarah M. Jenkins 7, Amy P. Gorsh 2, John J. Chen 3,8, Anastasia Zekeridou 1,2,3, Andrew McKeon 1,2,3, Eoin P. Flanagan 1,2,3, John R. Mills 2,3, Sean J. Pittock 1,2,3
1
Department of Neurology
Mayo Clinic
Rochester
Minnesota
USA
2
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester
Minnesota
USA
3
Center of MS and Autoimmune Neurology
Mayo Clinic
Rochester
Minnesota
USA
4
Division of Neurology, Department of Medicine, Faculty of Medicine
Khon Kaen University
Khon Kaen
Thailand
5
Department of Neurology
Massachusetts General Hospital
Boston
Massachusetts
USA
6
Department of Medicine
School of Medicine, College of Health Sciences, Makerere University
Kampala
Uganda
7
Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics
Mayo Clinic
Rochester
Minnesota
USA
8
Department of Ophthalmology
Mayo Clinic
Rochester
Minnesota
USA
Abstract
Objective This study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing.
Methods Prospective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the United States, Uganda, and the Republic of Guinea. Neuromyelitis optica spectrum disorder (NMOSD) patients and controls collected blood on filter paper...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Rare Diseases
Receive our newsletter to stay up to date with the latest news in Rare Diseases
